
Global IL-23 Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global IL-23 Receptor Antagonist market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of IL-23 Receptor Antagonist include Qyuns Therapeutics, China Medical System, Huadong Medicine, Bio-Thera Solutions, Teva, Sun Pharma, Sandoz, Samsung Bioepis and Janssen Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for IL-23 Receptor Antagonist, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of IL-23 Receptor Antagonist, also provides the sales of main regions and countries. Of the upcoming market potential for IL-23 Receptor Antagonist, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the IL-23 Receptor Antagonist sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global IL-23 Receptor Antagonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for IL-23 Receptor Antagonist sales, projected growth trends, production technology, application and end-user industry.
IL-23 Receptor Antagonist Segment by Company
Qyuns Therapeutics
China Medical System
Huadong Medicine
Bio-Thera Solutions
Teva
Sun Pharma
Sandoz
Samsung Bioepis
Janssen Pharmaceuticals
Eli Lilly
Celltrion
Biocon Biologics
Amgen
Almirall
AbbVie Biotechnology
IL-23 Receptor Antagonist Segment by Type
Briakinumab
Guselkumab
Mirikizumab
Risankizumab
Tildrakizumab
Ustekinumab
Other
IL-23 Receptor Antagonist Segment by Application
Plaque Psoriasis
Crohn's Disease
Psoriatic Arthritis
Other
IL-23 Receptor Antagonist Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-23 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of IL-23 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-23 Receptor Antagonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the IL-23 Receptor Antagonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of IL-23 Receptor Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of IL-23 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of IL-23 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global IL-23 Receptor Antagonist market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for IL-23 Receptor Antagonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of IL-23 Receptor Antagonist include Qyuns Therapeutics, China Medical System, Huadong Medicine, Bio-Thera Solutions, Teva, Sun Pharma, Sandoz, Samsung Bioepis and Janssen Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for IL-23 Receptor Antagonist, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of IL-23 Receptor Antagonist, also provides the sales of main regions and countries. Of the upcoming market potential for IL-23 Receptor Antagonist, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the IL-23 Receptor Antagonist sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global IL-23 Receptor Antagonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for IL-23 Receptor Antagonist sales, projected growth trends, production technology, application and end-user industry.
IL-23 Receptor Antagonist Segment by Company
Qyuns Therapeutics
China Medical System
Huadong Medicine
Bio-Thera Solutions
Teva
Sun Pharma
Sandoz
Samsung Bioepis
Janssen Pharmaceuticals
Eli Lilly
Celltrion
Biocon Biologics
Amgen
Almirall
AbbVie Biotechnology
IL-23 Receptor Antagonist Segment by Type
Briakinumab
Guselkumab
Mirikizumab
Risankizumab
Tildrakizumab
Ustekinumab
Other
IL-23 Receptor Antagonist Segment by Application
Plaque Psoriasis
Crohn's Disease
Psoriatic Arthritis
Other
IL-23 Receptor Antagonist Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-23 Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of IL-23 Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-23 Receptor Antagonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the IL-23 Receptor Antagonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of IL-23 Receptor Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of IL-23 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of IL-23 Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
199 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global IL-23 Receptor Antagonist Market Size, 2020 VS 2024 VS 2031
- 1.3 Global IL-23 Receptor Antagonist Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global IL-23 Receptor Antagonist Sales Estimates and Forecasts (2020-2031)
- 1.5 Global IL-23 Receptor Antagonist Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global IL-23 Receptor Antagonist Market Dynamics
- 2.1 IL-23 Receptor Antagonist Industry Trends
- 2.2 IL-23 Receptor Antagonist Industry Drivers
- 2.3 IL-23 Receptor Antagonist Industry Opportunities and Challenges
- 2.4 IL-23 Receptor Antagonist Industry Restraints
- 3 IL-23 Receptor Antagonist Market by Manufacturers
- 3.1 Global IL-23 Receptor Antagonist Revenue by Manufacturers (2020-2025)
- 3.2 Global IL-23 Receptor Antagonist Sales by Manufacturers (2020-2025)
- 3.3 Global IL-23 Receptor Antagonist Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global IL-23 Receptor Antagonist Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global IL-23 Receptor Antagonist Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global IL-23 Receptor Antagonist Manufacturers, Product Type & Application
- 3.7 Global IL-23 Receptor Antagonist Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global IL-23 Receptor Antagonist Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 IL-23 Receptor Antagonist Players Market Share by Revenue in 2024
- 3.8.3 2024 IL-23 Receptor Antagonist Tier 1, Tier 2, and Tier 3
- 4 IL-23 Receptor Antagonist Market by Type
- 4.1 IL-23 Receptor Antagonist Type Introduction
- 4.1.1 Briakinumab
- 4.1.2 Guselkumab
- 4.1.3 Mirikizumab
- 4.1.4 Risankizumab
- 4.1.5 Tildrakizumab
- 4.1.6 Ustekinumab
- 4.1.7 Other
- 4.2 Global IL-23 Receptor Antagonist Sales by Type
- 4.2.1 Global IL-23 Receptor Antagonist Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global IL-23 Receptor Antagonist Sales by Type (2020-2031)
- 4.2.3 Global IL-23 Receptor Antagonist Sales Market Share by Type (2020-2031)
- 4.3 Global IL-23 Receptor Antagonist Revenue by Type
- 4.3.1 Global IL-23 Receptor Antagonist Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global IL-23 Receptor Antagonist Revenue by Type (2020-2031)
- 4.3.3 Global IL-23 Receptor Antagonist Revenue Market Share by Type (2020-2031)
- 5 IL-23 Receptor Antagonist Market by Application
- 5.1 IL-23 Receptor Antagonist Application Introduction
- 5.1.1 Plaque Psoriasis
- 5.1.2 Crohn's Disease
- 5.1.3 Psoriatic Arthritis
- 5.1.4 Other
- 5.2 Global IL-23 Receptor Antagonist Sales by Application
- 5.2.1 Global IL-23 Receptor Antagonist Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global IL-23 Receptor Antagonist Sales by Application (2020-2031)
- 5.2.3 Global IL-23 Receptor Antagonist Sales Market Share by Application (2020-2031)
- 5.3 Global IL-23 Receptor Antagonist Revenue by Application
- 5.3.1 Global IL-23 Receptor Antagonist Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global IL-23 Receptor Antagonist Revenue by Application (2020-2031)
- 5.3.3 Global IL-23 Receptor Antagonist Revenue Market Share by Application (2020-2031)
- 6 Global IL-23 Receptor Antagonist Sales by Region
- 6.1 Global IL-23 Receptor Antagonist Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global IL-23 Receptor Antagonist Sales by Region (2020-2031)
- 6.2.1 Global IL-23 Receptor Antagonist Sales by Region (2020-2025)
- 6.2.2 Global IL-23 Receptor Antagonist Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America IL-23 Receptor Antagonist Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America IL-23 Receptor Antagonist Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe IL-23 Receptor Antagonist Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe IL-23 Receptor Antagonist Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific IL-23 Receptor Antagonist Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific IL-23 Receptor Antagonist Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa IL-23 Receptor Antagonist Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa IL-23 Receptor Antagonist Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global IL-23 Receptor Antagonist Revenue by Region
- 7.1 Global IL-23 Receptor Antagonist Revenue by Region
- 7.1.1 Global IL-23 Receptor Antagonist Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global IL-23 Receptor Antagonist Revenue by Region (2020-2025)
- 7.1.3 Global IL-23 Receptor Antagonist Revenue by Region (2026-2031)
- 7.1.4 Global IL-23 Receptor Antagonist Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America IL-23 Receptor Antagonist Revenue (2020-2031)
- 7.2.2 North America IL-23 Receptor Antagonist Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe IL-23 Receptor Antagonist Revenue (2020-2031)
- 7.3.2 Europe IL-23 Receptor Antagonist Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific IL-23 Receptor Antagonist Revenue (2020-2031)
- 7.4.2 Asia-Pacific IL-23 Receptor Antagonist Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa IL-23 Receptor Antagonist Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa IL-23 Receptor Antagonist Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Qyuns Therapeutics
- 8.1.1 Qyuns Therapeutics Comapny Information
- 8.1.2 Qyuns Therapeutics Business Overview
- 8.1.3 Qyuns Therapeutics IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Qyuns Therapeutics IL-23 Receptor Antagonist Product Portfolio
- 8.1.5 Qyuns Therapeutics Recent Developments
- 8.2 China Medical System
- 8.2.1 China Medical System Comapny Information
- 8.2.2 China Medical System Business Overview
- 8.2.3 China Medical System IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 China Medical System IL-23 Receptor Antagonist Product Portfolio
- 8.2.5 China Medical System Recent Developments
- 8.3 Huadong Medicine
- 8.3.1 Huadong Medicine Comapny Information
- 8.3.2 Huadong Medicine Business Overview
- 8.3.3 Huadong Medicine IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Huadong Medicine IL-23 Receptor Antagonist Product Portfolio
- 8.3.5 Huadong Medicine Recent Developments
- 8.4 Bio-Thera Solutions
- 8.4.1 Bio-Thera Solutions Comapny Information
- 8.4.2 Bio-Thera Solutions Business Overview
- 8.4.3 Bio-Thera Solutions IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Bio-Thera Solutions IL-23 Receptor Antagonist Product Portfolio
- 8.4.5 Bio-Thera Solutions Recent Developments
- 8.5 Teva
- 8.5.1 Teva Comapny Information
- 8.5.2 Teva Business Overview
- 8.5.3 Teva IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Teva IL-23 Receptor Antagonist Product Portfolio
- 8.5.5 Teva Recent Developments
- 8.6 Sun Pharma
- 8.6.1 Sun Pharma Comapny Information
- 8.6.2 Sun Pharma Business Overview
- 8.6.3 Sun Pharma IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Sun Pharma IL-23 Receptor Antagonist Product Portfolio
- 8.6.5 Sun Pharma Recent Developments
- 8.7 Sandoz
- 8.7.1 Sandoz Comapny Information
- 8.7.2 Sandoz Business Overview
- 8.7.3 Sandoz IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Sandoz IL-23 Receptor Antagonist Product Portfolio
- 8.7.5 Sandoz Recent Developments
- 8.8 Samsung Bioepis
- 8.8.1 Samsung Bioepis Comapny Information
- 8.8.2 Samsung Bioepis Business Overview
- 8.8.3 Samsung Bioepis IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Samsung Bioepis IL-23 Receptor Antagonist Product Portfolio
- 8.8.5 Samsung Bioepis Recent Developments
- 8.9 Janssen Pharmaceuticals
- 8.9.1 Janssen Pharmaceuticals Comapny Information
- 8.9.2 Janssen Pharmaceuticals Business Overview
- 8.9.3 Janssen Pharmaceuticals IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Janssen Pharmaceuticals IL-23 Receptor Antagonist Product Portfolio
- 8.9.5 Janssen Pharmaceuticals Recent Developments
- 8.10 Eli Lilly
- 8.10.1 Eli Lilly Comapny Information
- 8.10.2 Eli Lilly Business Overview
- 8.10.3 Eli Lilly IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Eli Lilly IL-23 Receptor Antagonist Product Portfolio
- 8.10.5 Eli Lilly Recent Developments
- 8.11 Celltrion
- 8.11.1 Celltrion Comapny Information
- 8.11.2 Celltrion Business Overview
- 8.11.3 Celltrion IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Celltrion IL-23 Receptor Antagonist Product Portfolio
- 8.11.5 Celltrion Recent Developments
- 8.12 Biocon Biologics
- 8.12.1 Biocon Biologics Comapny Information
- 8.12.2 Biocon Biologics Business Overview
- 8.12.3 Biocon Biologics IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 Biocon Biologics IL-23 Receptor Antagonist Product Portfolio
- 8.12.5 Biocon Biologics Recent Developments
- 8.13 Amgen
- 8.13.1 Amgen Comapny Information
- 8.13.2 Amgen Business Overview
- 8.13.3 Amgen IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Amgen IL-23 Receptor Antagonist Product Portfolio
- 8.13.5 Amgen Recent Developments
- 8.14 Almirall
- 8.14.1 Almirall Comapny Information
- 8.14.2 Almirall Business Overview
- 8.14.3 Almirall IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 Almirall IL-23 Receptor Antagonist Product Portfolio
- 8.14.5 Almirall Recent Developments
- 8.15 AbbVie Biotechnology
- 8.15.1 AbbVie Biotechnology Comapny Information
- 8.15.2 AbbVie Biotechnology Business Overview
- 8.15.3 AbbVie Biotechnology IL-23 Receptor Antagonist Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.15.4 AbbVie Biotechnology IL-23 Receptor Antagonist Product Portfolio
- 8.15.5 AbbVie Biotechnology Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 IL-23 Receptor Antagonist Value Chain Analysis
- 9.1.1 IL-23 Receptor Antagonist Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 IL-23 Receptor Antagonist Production Mode & Process
- 9.2 IL-23 Receptor Antagonist Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 IL-23 Receptor Antagonist Distributors
- 9.2.3 IL-23 Receptor Antagonist Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.